SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4xi2'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1JLF_A_NVPA999_1 (HIV-1 RT A-CHAIN HIV-1 RT B-CHAIN)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 8	LEU A 486 VAL A 529 CYH A 527 GLY A 480	None	1.00A	1jlfA-4xi2A: undetectable 1jlfB-4xi2A: undetectable	1jlfA-4xi2A: 22.41 1jlfB-4xi2A: 22.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MUO_A_ADNA1_1 (AURORA-RELATED KINASE 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 GLY A 409 VAL A 416 ALA A 428 TYR A 476 LEU A 528	None	0.99A	1muoA-4xi2A: 18.3	1muoA-4xi2A: 23.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T9U_A_CPFA5002_1 (ACRIFLAVINE RESISTANCE PROTEIN B)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 6	PHE A 559 ASN A 603 ARG A 525 ASN A 526	None	1.46A	1t9uA-4xi2A: undetectable	1t9uA-4xi2A: 17.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	VAL A 416 ALA A 428 THR A 474 LEU A 512 HIS A 519	None	0.52A	1uwjA-4xi2A: 7.8	1uwjA-4xi2A: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1X70_A_715A801_2 (DIPEPTIDYL PEPTIDASE IV)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	3 / 3	ARG A 641 SER A 592 TYR A 591	None	0.66A	1x70A-4xi2A: 3.7	1x70A-4xi2A: 19.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	ALA A 428 MET A 449 THR A 474 GLY A 480 CYH A 481 LEU A 483 LEU A 528 ASP A 539 PHE A 540	None	1.09A	1xkkA-4xi2A: 30.9	1xkkA-4xi2A: 25.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	MET A 449 THR A 474 GLY A 480 CYH A 481 LEU A 483 ARG A 487 LEU A 528 ASP A 539 PHE A 540	None	0.92A	1xkkA-4xi2A: 30.9	1xkkA-4xi2A: 25.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EVA_A_ADNA498_1 (TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 11	GLY A 409 GLY A 411 VAL A 416 ALA A 428 TYR A 476 LEU A 528	None	0.57A	2evaA-4xi2A: 19.8	2evaA-4xi2A: 22.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.72A	2gqgA-4xi2A: 27.4	2gqgA-4xi2A: 31.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.80A	2gqgB-4xi2A: 31.0	2gqgB-4xi2A: 31.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.71A	2xp2A-4xi2A: 31.2	2xp2A-4xi2A: 27.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LYS A 406 ALA A 428 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.95A	2y6oA-4xi2A: 30.4	2y6oA-4xi2A: 28.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.68A	2y7jB-4xi2A: 23.7	2y7jB-4xi2A: 22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.67A	2zvaA-4xi2A: 25.2	2zvaA-4xi2A: 27.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	LEU A 408 ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528	None	0.51A	3aoxA-4xi2A: 25.1	3aoxA-4xi2A: 28.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	10 / 12	VAL A 416 ALA A 428 MET A 449 LEU A 460 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540 LEU A 542	None	0.87A	3bbtB-4xi2A: 30.9	3bbtB-4xi2A: 25.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_D_FMMD91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	VAL A 416 ALA A 428 MET A 449 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540 LEU A 542	None	0.90A	3bbtD-4xi2A: 27.0	3bbtD-4xi2A: 25.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 10	LEU A 408 VAL A 416 VAL A 458 ILE A 472 VAL A 537	None	0.87A	3cs9A-4xi2A: 25.1	3cs9A-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	ALA A 428 LEU A 457 THR A 474 GLY A 480 HIS A 519 LEU A 528	None	0.89A	3cs9A-4xi2A: 25.1	3cs9A-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 LEU A 528	None	0.91A	3cs9A-4xi2A: 25.1	3cs9A-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 VAL A 416 VAL A 458 ILE A 472 LEU A 528 VAL A 537	None	1.16A	3cs9B-4xi2A: 24.9	3cs9B-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 9	LEU A 408 VAL A 416 ILE A 472 MET A 477 VAL A 537	None	1.21A	3cs9C-4xi2A: 24.8	3cs9C-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 9	LEU A 408 VAL A 416 VAL A 458 ILE A 472 VAL A 537	None	0.94A	3cs9C-4xi2A: 24.8	3cs9C-4xi2A: 31.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	LEU A 408 VAL A 416 ALA A 428 THR A 474 TYR A 476 LEU A 528	None	0.77A	3g0fB-4xi2A: 28.6	3g0fB-4xi2A: 26.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.76A	3g5dA-4xi2A: 24.3	3g5dA-4xi2A: 28.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480	None	0.73A	3g5dA-4xi2A: 24.3	3g5dA-4xi2A: 28.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.71A	3g5dB-4xi2A: 24.4	3g5dB-4xi2A: 28.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.77A	3k54A-4xi2A: 28.3	3k54A-4xi2A: 65.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 GLY A 409 VAL A 416 ALA A 428 VAL A 458 TYR A 476 CYH A 481 LEU A 528	None	1.26A	3lxkA-4xi2A: 27.8	3lxkA-4xi2A: 25.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 11	ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.67A	3miyA-4xi2A: 29.4	3miyA-4xi2A: 42.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 9	ALA A 428 MET A 477 GLY A 480 LEU A 528 SER A 538	None	0.57A	3miyB-4xi2A: 32.6	3miyB-4xi2A: 42.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.87A	3octA-4xi2A: 14.5	3octA-4xi2A: 97.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_B_1N1B1000_1 (P38A)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	GLY A 409 VAL A 416 ALA A 428 THR A 474 ASP A 539	None	0.49A	3ohtB-4xi2A: 6.1	3ohtB-4xi2A: 22.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	ALA A 428 LEU A 457 VAL A 458 THR A 474 GLY A 480 HIS A 519	None	0.88A	3oxzA-4xi2A: 29.8	3oxzA-4xi2A: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 9	ILE A 472 MET A 477 ARG A 520 LEU A 528 VAL A 537	None	1.16A	3oxzA-4xi2A: 29.7	3oxzA-4xi2A: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 9	LEU A 408 ILE A 472 MET A 477 LEU A 528 VAL A 537	None	1.15A	3oxzA-4xi2A: 29.7	3oxzA-4xi2A: 38.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3QLG_A_1N1A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.71A	3qlgA-4xi2A: 24.1	3qlgA-4xi2A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528 ASP A 539	None	0.84A	3qlgB-4xi2A: 24.4	3qlgB-4xi2A: 27.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.83A	3sxrA-4xi2A: 32.0	3sxrA-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 SER A 538	None	0.69A	3sxrA-4xi2A: 32.0	3sxrA-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.88A	3sxrB-4xi2A: 31.7	3sxrB-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 SER A 538	None	0.92A	3sxrB-4xi2A: 31.7	3sxrB-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.78A	3ue4A-4xi2A: 30.3	3ue4A-4xi2A: 33.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.85A	3ue4B-4xi2A: 30.1	3ue4B-4xi2A: 33.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	LEU A 408 GLY A 409 ALA A 428 GLY A 480 PHE A 540 LEU A 542	None	1.00A	3wzdA-4xi2A: 29.3	3wzdA-4xi2A: 24.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.65A	4anqA-4xi2A: 31.3	4anqA-4xi2A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.66A	4ansA-4xi2A: 31.2	4ansA-4xi2A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CKJ_A_ADNA2014_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	LEU A 408 GLY A 409 VAL A 416 ALA A 428 TYR A 476 LEU A 528	None	0.50A	4ckjA-4xi2A: 27.8	4ckjA-4xi2A: 27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.96A	4hjoA-4xi2A: 31.8	4hjoA-4xi2A: 23.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KS8_A_B49A701_1 (SERINE/THREONINE-PRO TEIN KINASE PAK 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	ALA A 428 VAL A 458 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.77A	4ks8A-4xi2A: 24.4	4ks8A-4xi2A: 20.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	ILE A 472 ASN A 526 ASP A 539 PHE A 540 GLY A 541 MET A 437	None	1.31A	4lmnA-4xi2A: 24.9	4lmnA-4xi2A: 20.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480	None	0.64A	4mxoA-4xi2A: 29.9	4mxoA-4xi2A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.69A	4mxoB-4xi2A: 24.1	4mxoB-4xi2A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.72A	4mxxA-4xi2A: 24.0	4mxxA-4xi2A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.67A	4mxxB-4xi2A: 25.5	4mxxB-4xi2A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.62A	4mxyA-4xi2A: 26.4	4mxyA-4xi2A: 27.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 TYR A 476 GLY A 480 LEU A 528	None	0.54A	4mxyB-4xi2A: 30.1	4mxyB-4xi2A: 27.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.62A	4mxzA-4xi2A: 26.4	4mxzA-4xi2A: 27.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 TYR A 476 GLY A 480 LEU A 528	None	0.54A	4mxzB-4xi2A: 30.1	4mxzB-4xi2A: 27.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	1.02A	4otwA-4xi2A: 28.0	4otwA-4xi2A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 11	LEU A 408 VAL A 416 ALA A 428 TYR A 476 MET A 477 GLY A 480 ASN A 526 LEU A 528	None	0.69A	4u5jA-4xi2A: 24.4	4u5jA-4xi2A: 28.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 9	LEU A 408 VAL A 416 ALA A 428 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.67A	4u5jB-4xi2A: 24.3	4u5jB-4xi2A: 28.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 9	LEU A 408 VAL A 416 LYS A 430 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	1.08A	4u5jB-4xi2A: 24.3	4u5jB-4xi2A: 28.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 11	LEU A 408 ALA A 428 THR A 474 MET A 477 GLY A 480 ASN A 526 LEU A 528	None	0.63A	4wa9A-4xi2A: 27.8	4wa9A-4xi2A: 33.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 6	LEU A 408 ALA A 428 MET A 477 LEU A 528	None	0.73A	4wboC-4xi2A: 16.4	4wboC-4xi2A: 22.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.77A	4xeyA-4xi2A: 30.6	4xeyA-4xi2A: 37.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.74A	4xeyB-4xi2A: 30.1	4xeyB-4xi2A: 37.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 ALA A 428 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.86A	4xliA-4xi2A: 24.8	4xliA-4xi2A: 30.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.81A	4xliB-4xi2A: 27.1	4xliB-4xi2A: 30.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XOY_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 6	ALA A 428 LYS A 430 MET A 477 LEU A 528	None	0.48A	4xoyA-4xi2A: undetectable	4xoyA-4xi2A: 21.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XP3_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 6	ALA A 428 LYS A 430 MET A 477 LEU A 528	None	0.37A	4xp3A-4xi2A: 22.0	4xp3A-4xi2A: 21.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 9	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.75A	5aaaA-4xi2A: 31.8	5aaaA-4xi2A: 27.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 10	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.56A	5aacA-4xi2A: 31.4	5aacA-4xi2A: 27.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 ALA A 428 LYS A 430 THR A 474 GLY A 480 LEU A 528	None	0.82A	5h2uA-4xi2A: 34.0	5h2uA-4xi2A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_2 (PROTEIN-TYROSINE KINASE 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	3 / 3	ILE A 472 MET A 477 ASP A 539	None	0.68A	5h2uA-4xi2A: 34.0	5h2uA-4xi2A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	LEU A 408 ALA A 428 THR A 474 GLY A 480 LEU A 528 ASP A 539	None	0.95A	5h2uC-4xi2A: 30.3	5h2uC-4xi2A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 ALA A 428 LYS A 430 ILE A 472 LEU A 528 ASP A 539	None	0.65A	5h2uD-4xi2A: 34.0	5h2uD-4xi2A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 VAL A 416 ALA A 428 LYS A 430 THR A 474 LEU A 528 ASP A 539	None	0.79A	5h2uD-4xi2A: 34.0	5h2uD-4xi2A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	VAL A 416 ALA A 428 ILE A 472 THR A 474 TYR A 476 PHE A 540	None	0.83A	5hesA-4xi2A: 10.0	5hesA-4xi2A: 19.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	VAL A 416 ALA A 428 ILE A 472 THR A 474 TYR A 476 PHE A 540	None	0.76A	5hesB-4xi2A: 26.5	5hesB-4xi2A: 19.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	GLY A 411 VAL A 416 ALA A 428 ILE A 472 THR A 474	None	0.64A	5hieA-4xi2A: 10.2	5hieA-4xi2A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	GLY A 411 VAL A 416 ALA A 428 ILE A 472 THR A 474	None	0.65A	5hieB-4xi2A: 10.2	5hieB-4xi2A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	GLY A 411 VAL A 416 ALA A 428 ILE A 472 THR A 474	None	0.66A	5hieD-4xi2A: 23.6	5hieD-4xi2A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	ALA A 428 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.84A	5i9xA-4xi2A: 30.5	5i9xA-4xi2A: 29.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	ALA A 428 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.77A	5i9yA-4xi2A: 27.0	5i9yA-4xi2A: 29.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	10 / 12	GLY A 411 VAL A 416 ALA A 428 MET A 449 ILE A 472 THR A 474 GLY A 480 LEU A 528 SER A 538 PHE A 540	None	0.56A	5p9iA-4xi2A: 41.2	5p9iA-4xi2A: 94.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	GLY A 411 VAL A 416 LYS A 430 MET A 449 ILE A 472 GLY A 480 LEU A 528 SER A 538 PHE A 540	None	0.81A	5p9iA-4xi2A: 41.2	5p9iA-4xi2A: 94.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	10 / 12	VAL A 416 ALA A 428 MET A 449 ILE A 472 THR A 474 GLY A 480 ASN A 484 LEU A 528 SER A 538 PHE A 540	None	0.71A	5p9iA-4xi2A: 41.2	5p9iA-4xi2A: 94.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	9 / 12	VAL A 416 LYS A 430 MET A 449 ILE A 472 GLY A 480 ASN A 484 LEU A 528 SER A 538 PHE A 540	None	0.90A	5p9iA-4xi2A: 41.2	5p9iA-4xi2A: 94.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_2 (TYROSINE-PROTEIN KINASE BTK)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 5	LEU A 408 TYR A 476 MET A 477 CYH A 481 ASP A 539	None	0.62A	5p9iA-4xi2A: 41.2	5p9iA-4xi2A: 94.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5U63_A_ACTA406_0 (THIOREDOXIN REDUCTASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	3 / 3	HIS A 519 SER A 538 ARG A 525	None	0.96A	5u63A-4xi2A: undetectable	5u63A-4xi2A: 20.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VLM_E_CVIE301_0 (REGULATORY PROTEIN TETR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	GLU A 567 LEU A 569 ILE A 610 ARG A 615 VAL A 585	None	1.43A	5vlmE-4xi2A: undetectable	5vlmE-4xi2A: 17.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	LEU A 408 GLY A 409 VAL A 416 ALA A 428 MET A 449 CYH A 481 LEU A 528 ASP A 539	None	0.98A	5yu9A-4xi2A: 29.9	5yu9A-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	LEU A 408 GLY A 409 VAL A 416 LYS A 430 MET A 449 CYH A 481 ASP A 539	None	1.09A	5yu9A-4xi2A: 29.9	5yu9A-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	GLY A 409 VAL A 416 ALA A 428 MET A 449 CYH A 481 LEU A 528 ASP A 539	None	0.88A	5yu9B-4xi2A: 26.7	5yu9B-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_C_1E8C1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 ASP A 539	None	0.82A	5yu9C-4xi2A: 29.9	5yu9C-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 LEU A 528 ASP A 539 LEU A 542	None	0.75A	5yu9D-4xi2A: 25.7	5yu9D-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	6 / 12	VAL A 416 LYS A 430 MET A 449 CYH A 481 ASP A 539 LEU A 542	None	1.04A	5yu9D-4xi2A: 25.7	5yu9D-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	3 / 3	TYR A 476 LEU A 528 ASP A 539	None	0.60A	5zv2B-4xi2A: 30.0	5zv2B-4xi2A: 10.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BSD_A_1N1A901_0 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	7 / 12	VAL A 416 ALA A 428 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.73A	6bsdA-4xi2A: 25.3	6bsdA-4xi2A: 10.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BXL_B_SAMB401_0 (2-(3-AMINO-3-CARBOXY PROPYL)HISTIDINE SYNTHASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	LEU A 542 GLY A 541 SER A 564 VAL A 568 ARG A 544	None	1.33A	6bxlB-4xi2A: undetectable	6bxlB-4xi2A: 24.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BXM_A_SAMA402_0 (DIPHTHAMIDE BIOSYNTHESIS ENZYME DPH2)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	LEU A 542 GLY A 541 SER A 564 VAL A 568 ARG A 544	None	1.22A	6bxmA-4xi2A: undetectable	6bxmA-4xi2A: 20.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BXN_B_SAMB901_0 (DIPHTHAMIDE BIOSYNTHESIS ENZYME DPH2)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	5 / 12	LEU A 542 GLY A 541 SER A 564 VAL A 568 ARG A 544	None	1.35A	6bxnB-4xi2A: undetectable	6bxnB-4xi2A: 20.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6EQP_A_BUWA601_1 (CHOLINESTERASE)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	4 / 8	GLY A 389 GLN A 459 THR A 387 SER A 394	None	0.86A	6eqpA-4xi2A: undetectable	6eqpA-4xi2A: 13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FNM_A_1N1A1001_1 (-)	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	8 / 12	VAL A 416 ALA A 428 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528 SER A 538	None	0.67A	6fnmA-4xi2A: 30.7	6fnmA-4xi2A: 26.68

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1JLF_A_NVPA999_1","HIV-1 RT A-CHAIN;HIV-1 RT B-CHAIN","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"LEU A 486;VAL A 529;CYH A 527;GLY A 480","None","1.00A","1jlfA-4xi2A:undetectable;1jlfB-4xi2A:undetectable","1jlfA-4xi2A:22.41;1jlfB-4xi2A:22.07"],["1MUO_A_ADNA1_1","AURORA-RELATED KINASE 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;TYR A 476;LEU A 528","None","0.99A","1muoA-4xi2A:18.3","1muoA-4xi2A:23.01"],["1T9U_A_CPFA5002_1","ACRIFLAVINE RESISTANCE PROTEIN B","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"PHE A 559;ASN A 603;ARG A 525;ASN A 526","None","1.46A","1t9uA-4xi2A:undetectable","1t9uA-4xi2A:17.86"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"VAL A 416;ALA A 428;THR A 474;LEU A 512;HIS A 519","None","0.52A","1uwjA-4xi2A:7.8","1uwjA-4xi2A:23.73"],["1X70_A_715A801_2","DIPEPTIDYL PEPTIDASE IV","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",3,"ARG A 641;SER A 592;TYR A 591","None","0.66A","1x70A-4xi2A:3.7","1x70A-4xi2A:19.86"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"ALA A 428;MET A 449;THR A 474;GLY A 480;CYH A 481;LEU A 483;LEU A 528;ASP A 539;PHE A 540","None","1.09A","1xkkA-4xi2A:30.9","1xkkA-4xi2A:25.87"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"MET A 449;THR A 474;GLY A 480;CYH A 481;LEU A 483;ARG A 487;LEU A 528;ASP A 539;PHE A 540","None","0.92A","1xkkA-4xi2A:30.9","1xkkA-4xi2A:25.87"],["2EVA_A_ADNA498_1","TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"GLY A 409;GLY A 411;VAL A 416;ALA A 428;TYR A 476;LEU A 528","None","0.57A","2evaA-4xi2A:19.8","2evaA-4xi2A:22.04"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.72A","2gqgA-4xi2A:27.4","2gqgA-4xi2A:31.84"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.80A","2gqgB-4xi2A:31.0","2gqgB-4xi2A:31.84"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.71A","2xp2A-4xi2A:31.2","2xp2A-4xi2A:27.16"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LYS A 406;ALA A 428;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.95A","2y6oA-4xi2A:30.4","2y6oA-4xi2A:28.17"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.68A","2y7jB-4xi2A:23.7","2y7jB-4xi2A:22.78"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.67A","2zvaA-4xi2A:25.2","2zvaA-4xi2A:27.05"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528","None","0.51A","3aoxA-4xi2A:25.1","3aoxA-4xi2A:28.13"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",10,"VAL A 416;ALA A 428;MET A 449;LEU A 460;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540;LEU A 542","None","0.87A","3bbtB-4xi2A:30.9","3bbtB-4xi2A:25.77"],["3BBT_D_FMMD91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"VAL A 416;ALA A 428;MET A 449;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540;LEU A 542","None","0.90A","3bbtD-4xi2A:27.0","3bbtD-4xi2A:25.77"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 408;VAL A 416;VAL A 458;ILE A 472;VAL A 537","None","0.87A","3cs9A-4xi2A:25.1","3cs9A-4xi2A:31.60"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;HIS A 519;LEU A 528","None","0.89A","3cs9A-4xi2A:25.1","3cs9A-4xi2A:31.60"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;LEU A 528","None","0.91A","3cs9A-4xi2A:25.1","3cs9A-4xi2A:31.60"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;VAL A 458;ILE A 472;LEU A 528;VAL A 537","None","1.16A","3cs9B-4xi2A:24.9","3cs9B-4xi2A:31.60"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 408;VAL A 416;ILE A 472;MET A 477;VAL A 537","None","1.21A","3cs9C-4xi2A:24.8","3cs9C-4xi2A:31.60"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 408;VAL A 416;VAL A 458;ILE A 472;VAL A 537","None","0.94A","3cs9C-4xi2A:24.8","3cs9C-4xi2A:31.60"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;THR A 474;TYR A 476;LEU A 528","None","0.77A","3g0fB-4xi2A:28.6","3g0fB-4xi2A:26.04"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.76A","3g5dA-4xi2A:24.3","3g5dA-4xi2A:28.24"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480","None","0.73A","3g5dA-4xi2A:24.3","3g5dA-4xi2A:28.24"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.71A","3g5dB-4xi2A:24.4","3g5dB-4xi2A:28.24"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.77A","3k54A-4xi2A:28.3","3k54A-4xi2A:65.88"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;VAL A 458;TYR A 476;CYH A 481;LEU A 528","None","1.26A","3lxkA-4xi2A:27.8","3lxkA-4xi2A:25.62"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.67A","3miyA-4xi2A:29.4","3miyA-4xi2A:42.94"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"ALA A 428;MET A 477;GLY A 480;LEU A 528;SER A 538","None","0.57A","3miyB-4xi2A:32.6","3miyB-4xi2A:42.94"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.87A","3octA-4xi2A:14.5","3octA-4xi2A:97.39"],["3OHT_B_1N1B1000_1","P38A","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"GLY A 409;VAL A 416;ALA A 428;THR A 474;ASP A 539","None","0.49A","3ohtB-4xi2A:6.1","3ohtB-4xi2A:22.63"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ALA A 428;LEU A 457;VAL A 458;THR A 474;GLY A 480;HIS A 519","None","0.88A","3oxzA-4xi2A:29.8","3oxzA-4xi2A:38.33"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"ILE A 472;MET A 477;ARG A 520;LEU A 528;VAL A 537","None","1.16A","3oxzA-4xi2A:29.7","3oxzA-4xi2A:38.33"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 408;ILE A 472;MET A 477;LEU A 528;VAL A 537","None","1.15A","3oxzA-4xi2A:29.7","3oxzA-4xi2A:38.33"],["3QLG_A_1N1A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.71A","3qlgA-4xi2A:24.1","3qlgA-4xi2A:27.78"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528;ASP A 539","None","0.84A","3qlgB-4xi2A:24.4","3qlgB-4xi2A:27.78"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.83A","3sxrA-4xi2A:32.0","3sxrA-4xi2A:43.03"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;SER A 538","None","0.69A","3sxrA-4xi2A:32.0","3sxrA-4xi2A:43.03"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.88A","3sxrB-4xi2A:31.7","3sxrB-4xi2A:43.03"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;SER A 538","None","0.92A","3sxrB-4xi2A:31.7","3sxrB-4xi2A:43.03"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.78A","3ue4A-4xi2A:30.3","3ue4A-4xi2A:33.17"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.85A","3ue4B-4xi2A:30.1","3ue4B-4xi2A:33.17"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;GLY A 409;ALA A 428;GLY A 480;PHE A 540;LEU A 542","None","1.00A","3wzdA-4xi2A:29.3","3wzdA-4xi2A:24.26"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.65A","4anqA-4xi2A:31.3","4anqA-4xi2A:27.52"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.66A","4ansA-4xi2A:31.2","4ansA-4xi2A:27.52"],["4CKJ_A_ADNA2014_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;TYR A 476;LEU A 528","None","0.50A","4ckjA-4xi2A:27.8","4ckjA-4xi2A:27.17"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.96A","4hjoA-4xi2A:31.8","4hjoA-4xi2A:23.61"],["4KS8_A_B49A701_1","SERINE\/THREONINE-PROTEIN KINASE PAK 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ALA A 428;VAL A 458;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.77A","4ks8A-4xi2A:24.4","4ks8A-4xi2A:20.73"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ILE A 472;ASN A 526;ASP A 539;PHE A 540;GLY A 541;MET A 437","None","1.31A","4lmnA-4xi2A:24.9","4lmnA-4xi2A:20.70"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480","None","0.64A","4mxoA-4xi2A:29.9","4mxoA-4xi2A:27.78"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.69A","4mxoB-4xi2A:24.1","4mxoB-4xi2A:27.78"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.72A","4mxxA-4xi2A:24.0","4mxxA-4xi2A:27.78"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.67A","4mxxB-4xi2A:25.5","4mxxB-4xi2A:27.78"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.62A","4mxyA-4xi2A:26.4","4mxyA-4xi2A:27.31"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;TYR A 476;GLY A 480;LEU A 528","None","0.54A","4mxyB-4xi2A:30.1","4mxyB-4xi2A:27.31"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.62A","4mxzA-4xi2A:26.4","4mxzA-4xi2A:27.31"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;TYR A 476;GLY A 480;LEU A 528","None","0.54A","4mxzB-4xi2A:30.1","4mxzB-4xi2A:27.31"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","1.02A","4otwA-4xi2A:28.0","4otwA-4xi2A:22.06"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;TYR A 476;MET A 477;GLY A 480;ASN A 526;LEU A 528","None","0.69A","4u5jA-4xi2A:24.4","4u5jA-4xi2A:28.01"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.67A","4u5jB-4xi2A:24.3","4u5jB-4xi2A:28.01"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;LYS A 430;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","1.08A","4u5jB-4xi2A:24.3","4u5jB-4xi2A:28.01"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;ALA A 428;THR A 474;MET A 477;GLY A 480;ASN A 526;LEU A 528","None","0.63A","4wa9A-4xi2A:27.8","4wa9A-4xi2A:33.41"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"LEU A 408;ALA A 428;MET A 477;LEU A 528","None","0.73A","4wboC-4xi2A:16.4","4wboC-4xi2A:22.07"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.77A","4xeyA-4xi2A:30.6","4xeyA-4xi2A:37.67"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.74A","4xeyB-4xi2A:30.1","4xeyB-4xi2A:37.67"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;ALA A 428;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.86A","4xliA-4xi2A:24.8","4xliA-4xi2A:30.54"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.81A","4xliB-4xi2A:27.1","4xliB-4xi2A:30.54"],["4XOY_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"ALA A 428;LYS A 430;MET A 477;LEU A 528","None","0.48A","4xoyA-4xi2A:undetectable","4xoyA-4xi2A:21.15"],["4XP3_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"ALA A 428;LYS A 430;MET A 477;LEU A 528","None","0.37A","4xp3A-4xi2A:22.0","4xp3A-4xi2A:21.15"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.75A","5aaaA-4xi2A:31.8","5aaaA-4xi2A:27.16"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.56A","5aacA-4xi2A:31.4","5aacA-4xi2A:27.16"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;THR A 474;GLY A 480;LEU A 528","None","0.82A","5h2uA-4xi2A:34.0","5h2uA-4xi2A:23.39"],["5H2U_A_1N1A501_2","PROTEIN-TYROSINE KINASE 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",3,"ILE A 472;MET A 477;ASP A 539","None","0.68A","5h2uA-4xi2A:34.0","5h2uA-4xi2A:23.39"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"LEU A 408;ALA A 428;THR A 474;GLY A 480;LEU A 528;ASP A 539","None","0.95A","5h2uC-4xi2A:30.3","5h2uC-4xi2A:23.39"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;ILE A 472;LEU A 528;ASP A 539","None","0.65A","5h2uD-4xi2A:34.0","5h2uD-4xi2A:23.39"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;THR A 474;LEU A 528;ASP A 539","None","0.79A","5h2uD-4xi2A:34.0","5h2uD-4xi2A:23.39"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"VAL A 416;ALA A 428;ILE A 472;THR A 474;TYR A 476;PHE A 540","None","0.83A","5hesA-4xi2A:10.0","5hesA-4xi2A:19.33"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"VAL A 416;ALA A 428;ILE A 472;THR A 474;TYR A 476;PHE A 540","None","0.76A","5hesB-4xi2A:26.5","5hesB-4xi2A:19.33"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"GLY A 411;VAL A 416;ALA A 428;ILE A 472;THR A 474","None","0.64A","5hieA-4xi2A:10.2","5hieA-4xi2A:24.24"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"GLY A 411;VAL A 416;ALA A 428;ILE A 472;THR A 474","None","0.65A","5hieB-4xi2A:10.2","5hieB-4xi2A:24.24"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"GLY A 411;VAL A 416;ALA A 428;ILE A 472;THR A 474","None","0.66A","5hieD-4xi2A:23.6","5hieD-4xi2A:24.24"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"ALA A 428;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.84A","5i9xA-4xi2A:30.5","5i9xA-4xi2A:29.37"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"ALA A 428;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.77A","5i9yA-4xi2A:27.0","5i9yA-4xi2A:29.37"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",10,"GLY A 411;VAL A 416;ALA A 428;MET A 449;ILE A 472;THR A 474;GLY A 480;LEU A 528;SER A 538;PHE A 540","None","0.56A","5p9iA-4xi2A:41.2","5p9iA-4xi2A:94.52"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"GLY A 411;VAL A 416;LYS A 430;MET A 449;ILE A 472;GLY A 480;LEU A 528;SER A 538;PHE A 540","None","0.81A","5p9iA-4xi2A:41.2","5p9iA-4xi2A:94.52"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",10,"VAL A 416;ALA A 428;MET A 449;ILE A 472;THR A 474;GLY A 480;ASN A 484;LEU A 528;SER A 538;PHE A 540","None","0.71A","5p9iA-4xi2A:41.2","5p9iA-4xi2A:94.52"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",9,"VAL A 416;LYS A 430;MET A 449;ILE A 472;GLY A 480;ASN A 484;LEU A 528;SER A 538;PHE A 540","None","0.90A","5p9iA-4xi2A:41.2","5p9iA-4xi2A:94.52"],["5P9I_A_1E8A701_2","TYROSINE-PROTEIN KINASE BTK","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 408;TYR A 476;MET A 477;CYH A 481;ASP A 539","None","0.62A","5p9iA-4xi2A:41.2","5p9iA-4xi2A:94.52"],["5U63_A_ACTA406_0","THIOREDOXIN REDUCTASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",3,"HIS A 519;SER A 538;ARG A 525","None","0.96A","5u63A-4xi2A:undetectable","5u63A-4xi2A:20.74"],["5VLM_E_CVIE301_0","REGULATORY PROTEIN TETR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"GLU A 567;LEU A 569;ILE A 610;ARG A 615;VAL A 585","None","1.43A","5vlmE-4xi2A:undetectable","5vlmE-4xi2A:17.63"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;MET A 449;CYH A 481;LEU A 528;ASP A 539","None","0.98A","5yu9A-4xi2A:29.9","5yu9A-4xi2A:11.21"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"LEU A 408;GLY A 409;VAL A 416;LYS A 430;MET A 449;CYH A 481;ASP A 539","None","1.09A","5yu9A-4xi2A:29.9","5yu9A-4xi2A:11.21"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"GLY A 409;VAL A 416;ALA A 428;MET A 449;CYH A 481;LEU A 528;ASP A 539","None","0.88A","5yu9B-4xi2A:26.7","5yu9B-4xi2A:11.21"],["5YU9_C_1E8C1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;ASP A 539","None","0.82A","5yu9C-4xi2A:29.9","5yu9C-4xi2A:11.21"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;LEU A 528;ASP A 539;LEU A 542","None","0.75A","5yu9D-4xi2A:25.7","5yu9D-4xi2A:11.21"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",6,"VAL A 416;LYS A 430;MET A 449;CYH A 481;ASP A 539;LEU A 542","None","1.04A","5yu9D-4xi2A:25.7","5yu9D-4xi2A:11.21"],["5ZV2_B_LEVB801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",3,"TYR A 476;LEU A 528;ASP A 539","None","0.60A","5zv2B-4xi2A:30.0","5zv2B-4xi2A:10.76"],["6BSD_A_1N1A901_0","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",7,"VAL A 416;ALA A 428;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.73A","6bsdA-4xi2A:25.3","6bsdA-4xi2A:10.23"],["6BXL_B_SAMB401_0","2-(3-AMINO-3-CARBOXYPROPYL)HISTIDINE SYNTHASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 542;GLY A 541;SER A 564;VAL A 568;ARG A 544","None","1.33A","6bxlB-4xi2A:undetectable","6bxlB-4xi2A:24.32"],["6BXM_A_SAMA402_0","DIPHTHAMIDE BIOSYNTHESIS ENZYME DPH2","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 542;GLY A 541;SER A 564;VAL A 568;ARG A 544","None","1.22A","6bxmA-4xi2A:undetectable","6bxmA-4xi2A:20.65"],["6BXN_B_SAMB901_0","DIPHTHAMIDE BIOSYNTHESIS ENZYME DPH2","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",5,"LEU A 542;GLY A 541;SER A 564;VAL A 568;ARG A 544","None","1.35A","6bxnB-4xi2A:undetectable","6bxnB-4xi2A:20.65"],["6EQP_A_BUWA601_1","CHOLINESTERASE","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",4,"GLY A 389;GLN A 459;THR A 387;SER A 394","None","0.86A","6eqpA-4xi2A:undetectable","6eqpA-4xi2A:13.62"],["6FNM_A_1N1A1001_1","-","4xi2","TYROSINE-PROTEIN KINASE BTK","Mus musculus",8,"VAL A 416;ALA A 428;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528;SER A 538","None","0.67A","6fnmA-4xi2A:30.7","6fnmA-4xi2A:26.68"]]